Patrick Schummer
YOU?
Author Swipe
View article: Brentuximab‐Vedotin als Mono‐ oder Kombinationstherapie bei kutanen peripheren T‐Zell‐Lymphomen – eine retrospektive Analyse
Brentuximab‐Vedotin als Mono‐ oder Kombinationstherapie bei kutanen peripheren T‐Zell‐Lymphomen – eine retrospektive Analyse Open
Zusammenfassung Hintergrund Kutane periphere T‐Zell‐Lymphome (PTCL) sind selten und zeigen einen aggressiven Verlauf mit limitiertem Therapieansprechen. Die Wirksamkeit von Brentuximab‐Vedotin bei kutanen PTCL wurde bisher nicht systematis…
View article: Brentuximab vedotin and radiotherapy for CD30‐positive cutaneous T‐cell lymphoma – a retrospective multicenter analysis
Brentuximab vedotin and radiotherapy for CD30‐positive cutaneous T‐cell lymphoma – a retrospective multicenter analysis Open
Summary Background and Objectives While brentuximab vedotin (BV) and radiotherapy (RTx) are established treatment options for CD30‐positive cutaneous T‐cell lymphoma (CTCL), data on their simultaneous or sequential use regarding efficacy a…
View article: Brentuximab vedotin as monotherapy or combination therapy for cutaneous peripheral T cell lymphoma – a retrospective study
Brentuximab vedotin as monotherapy or combination therapy for cutaneous peripheral T cell lymphoma – a retrospective study Open
Summary Background Cutaneous peripheral T cell lymphomas (PTCL) are rare and show an aggressive course with limited response to therapy. The efficacy of brentuximab vedotin in cutaneous peripheral T cell lymphomas has not yet been systemat…
View article: Re-exposition to ipilimumab plus nivolumab in metastatic Merkel cell carcinoma
Re-exposition to ipilimumab plus nivolumab in metastatic Merkel cell carcinoma Open
Background Merkel cell carcinoma (MCC) is a rare but highly aggressive cutaneous malignancy. Immune checkpoint inhibition (ICI) with PD-(L)1 blockade has significantly improved treatment outcomes in metastatic disease. In patients with pri…
View article: Adrenal Insufficiency after Long-term use of Topical Glucocorticoids in Patients with Advanced Cutaneous T-cell Lymphomas: A Case Series
Adrenal Insufficiency after Long-term use of Topical Glucocorticoids in Patients with Advanced Cutaneous T-cell Lymphomas: A Case Series Open
is missing (Short communication)
View article: Health‐related quality of life and its influencing factors in patients with primary cutaneous B‐cell lymphomas: A multicentric study in 100 patients
Health‐related quality of life and its influencing factors in patients with primary cutaneous B‐cell lymphomas: A multicentric study in 100 patients Open
Background Primary cutaneous B‐cell lymphomas (CBCL) are a group of rare malignant skin diseases that represent approximately 20%–30% of all primary cutaneous lymphomas (PCL). Previous studies revealed impaired health‐related quality of li…
View article: Neoadjuvant ipilimumab plus nivolumab in locally advanced melanoma: A real-world single-centre retrospective study
Neoadjuvant ipilimumab plus nivolumab in locally advanced melanoma: A real-world single-centre retrospective study Open
Background: Neoadjuvant immune-checkpoint inhibition (neoICI) with ipilimumab and nivolumab has shown high pathologic response rates as well as a long-lasting relapse-free survival in stage III melanoma patients. However, safety and effica…
View article: Response to First-Line Treatment with Immune-Checkpoint Inhibitors in Patients with Advanced Cutaneous Squamous Cell Carcinoma: A Multicenter, Retrospective Analysis from the German ADOReg Registry
Response to First-Line Treatment with Immune-Checkpoint Inhibitors in Patients with Advanced Cutaneous Squamous Cell Carcinoma: A Multicenter, Retrospective Analysis from the German ADOReg Registry Open
Cutaneous squamous cell carcinoma (cSCC) is a common malignancy of the skin and has an overall favorable outcome, except for patients with an advanced stage of the disease. The efficacy of checkpoint inhibitors (CPI) for advanced cSCC has …
View article: Ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma: a multicenter study of the prospective skin cancer registry ADOREG
Ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma: a multicenter study of the prospective skin cancer registry ADOREG Open
Merkel cell carcinoma is a rare, highly aggressive skin cancer with neuroendocrine differentiation. Immune checkpoint inhibition has significantly improved treatment outcomes in metastatic disease with response rates to programmed cell dea…
View article: Patient Preferences in Hidradenitis Suppurativa (APProach‐HS): a discrete choice experiment
Patient Preferences in Hidradenitis Suppurativa (APProach‐HS): a discrete choice experiment Open
Summary Background and Objectives Treatment options for moderate‐to‐severe hidradenitis suppurativa (HS) comprise antibiotics, biologics, and different surgical methods. These approaches differ substantially regarding the treatment process…
View article: Panel Sequencing of Primary Cutaneous B-Cell Lymphoma
Panel Sequencing of Primary Cutaneous B-Cell Lymphoma Open
Background: Primary cutaneous follicular B-cell lymphoma (PCFBCL) represents an indolent subtype of Non-Hodgkin’s lymphomas, being clinically characterized by slowly growing tumors of the skin and common cutaneous relapses, while only exhi…
View article: How representative are data from global trials on programmed death-1 blockade in melanoma?
How representative are data from global trials on programmed death-1 blockade in melanoma? Open
Linked Article: Bai et al. Br J Dermatol 2022; 187:401–410.
View article: Superior skin cancer classification by the combination of human and artificial intelligence
Superior skin cancer classification by the combination of human and artificial intelligence Open
Regarding the multiclass task, the combination of man and machine achieved an accuracy of 82.95%. This was 1.36% higher than the best of the two individual classifiers (81.59% achieved by the CNN). Owing to the class imbalance in the binar…
View article: Specific c-Jun target genes in malignant melanoma
Specific c-Jun target genes in malignant melanoma Open
A fundamental event in the development and progression of malignant melanoma is the de-regulation of cancer-relevant transcription factors. We recently showed that c-Jun is a main regulator of melanoma progression and, thus, is the most im…